Comparative Pharmacology
Head-to-head clinical analysis: CIBINQO versus REVUFORJ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIBINQO versus REVUFORJ.
CIBINQO vs REVUFORJ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIBINQO (abrocitinib) is a Janus kinase (JAK) inhibitor. It selectively inhibits JAK1, which modulates cytokine signaling involved in inflammatory pathways, including interleukin (IL)-4, IL-13, IL-31, and interferon-gamma, reducing the inflammatory response in atopic dermatitis.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
100 mg orally once daily, with or without food.
Oral, 500 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours in healthy subjects, supporting twice-daily dosing. No significant accumulation after multiple doses.
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
Primarily excreted via feces (69%) and urine (20%) after oral administration. Renal elimination accounts for <1% of unchanged drug. Biliary excretion is the major route for metabolites.
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Category C
Category C
JAK Inhibitor
JAK Inhibitor